title: Targeted immunotherapy in Hodgkin lymphoma.
abstract: In this issue of Blood, Rothe et al introduce a new principle of targeted Hodgkin lymphoma (HL) immunotherapy in their report from a phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13.
authors.affiliation: COPENHAGEN UNIVERSITY HOSPITAL.
authors.forename: Martin
authors.initials: M
authors.lastname: Hutchings
mesh_terms: D018033:Antibodies, Bispecific / Q000008:administration & dosage*; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008297:Male
chemical_list: D018033:Antibodies, Bispecific